Narazaciclib

DB19038InvestigationalSmall molecule

Narazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3, Platelet-derived growth factor receptor beta, and Mast/stem cell growth factor receptor Kit
Curator reviewed
Formula / weight: C₂₄H₂₇N₇O · 429.528 g/mol (avg)
Also known as: Pyrido(2,3-d)pyrimidine-6-carbonitrile, 8-cyclopentyl-7,8-dihydro-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-7-oxo-
Code names: HX-301 · ON-123300

Resolves to

Compound

UNIIQJ8RO3296GCAS1357470-29-1ChEMBLCHEMBL3115681

Structure

InChIKeyVADOZMZXXRBXNY-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=CC=C(NC2=NC=C3C=C(C#N)C(=O)N(C4CCCC4)C3=N2)C=C1

Targets

P36888FLT3P09619PDGFRBP10721KITP07333CSF1RQ00534CDK6P11802CDK4O00329PIK3CDO60285NUAK1

What you can answer from here — as of July 09, 2026

8Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

21+ReferencesStructured and connected to the statements they support

Which drugs share a target with Narazaciclib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account